Platelets Archives - EMEA

This site provides INTERCEPT product information for International audiences .

Bacterial contamination of platelet components, passive vs. active, surveillance, testing and pathogen reduction technologies

Bacterial contamination of platelet components, passive vs. active, surveillance, testing and pathogen reduction technologies

by jaycornell | May 6, 2025

Dr. Richard J. Benjamin, MBChB, PhD, FRCPath Cerus Corporation Concord, California, USA

Stanford Blood Center – the first blood center of its size to implement pathogen reduction for 100% of platelet components

Stanford Blood Center – the first blood center of its size to implement pathogen reduction for 100% of platelet components

by jaycornell | May 6, 2025

Stanford Blood Center California, United States

Case study: impact of pathogen inactivation on outdating rates and supply continuity

Case study: impact of pathogen inactivation on outdating rates and supply continuity

by jaycornell | May 6, 2025

Ms. Ragna Landrö, BSc The Blood Bank The National University Hospital of Iceland Reykjavík, Iceland

Case study: enabling double dose methodology on Reveos through pathogen inactivation

Case study: enabling double dose methodology on Reveos through pathogen inactivation

by jaycornell | May 6, 2025

Ms. Eleonore Tennby Cerus Europe B.V. Amersfoort, the Netherlands

How pools-of-pools contributes to optimising your PI platelet products

How pools-of-pools contributes to optimising your PI platelet products

by jaycornell | May 5, 2025

Mr. Jean-Marc Payrat Cerus Europe B.V. Amersfoort, the Netherlands

« Older Entries